SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000921895-22-002401
Filing Date
2022-08-11
Accepted
2022-08-11 16:48:12
Documents
1

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 8 TO THE SCHEDULE 13D sc13da807422cti_08112022.htm SC 13D/A 319605
  Complete submission text file 0000921895-22-002401.txt   321287
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Subject) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-48459 | Film No.: 221156590
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Business Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104 3125066500
BIOTECHNOLOGY VALUE FUND L P (Filed by) CIK: 0000918923 (see all company filings)

IRS No.: 363924731 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice
Office of Finance